Compare Stocks → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADVMNASDAQ:AXLANASDAQ:CGTXNASDAQ:CRDF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$10.19-7.4%$16.04$7.10▼$29.70$211.49M0.84241,171 shs347,096 shsAXLAAxcella Health$0.40-8.9%$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,700 shsCGTXCognition Therapeutics$1.99-0.5%$1.93$0.90▼$3.49$77.61M1.63197,143 shs114,823 shsCRDFCardiff Oncology$4.18+0.2%$4.17$0.94▼$6.42$186.76M1.941.49 million shs343,188 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies-3.00%-5.25%-31.51%+21.01%+21.95%AXLAAxcella Health0.00%0.00%0.00%0.00%-96.17%CGTXCognition Therapeutics+7.53%+5.82%+10.50%-17.70%+6.95%CRDFCardiff Oncology-4.36%-9.15%-28.72%+175.25%+185.62%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies4.0669 of 5 stars3.52.00.04.83.12.50.0AXLAAxcella HealthN/AN/AN/AN/AN/AN/AN/AN/ACGTXCognition Therapeutics3.64 of 5 stars3.55.00.00.03.84.20.0CRDFCardiff Oncology0.5342 of 5 stars3.52.00.00.00.00.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies3.00Buy$34.67240.20% UpsideAXLAAxcella HealthN/AN/AN/AN/ACGTXCognition Therapeutics3.00Buy$6.67235.01% UpsideCRDFCardiff Oncology3.00Buy$10.50151.20% UpsideCurrent Analyst RatingsLatest ADVM, CGTX, CRDF, and AXLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CGTXCognition TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/27/2024CGTXCognition TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.003/19/2024ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/6/2024CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $14.003/1/2024CRDFCardiff OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $7.002/6/2024ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $40.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$3.60M58.75N/AN/A$8.26 per share1.23AXLAAxcella HealthN/AN/AN/AN/A$1.42 per shareN/ACGTXCognition TherapeuticsN/AN/AN/AN/A$0.76 per shareN/ACRDFCardiff Oncology$490K381.15N/AN/A$1.56 per share2.68Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$11.60N/AN/AN/AN/A-98.65%-52.85%5/9/2024 (Estimated)AXLAAxcella Health-$81.19M-$19.25N/A∞N/AN/AN/A-259.91%N/ACGTXCognition Therapeutics-$25.79M-$0.86N/AN/AN/AN/A-83.48%-63.07%5/2/2024 (Estimated)CRDFCardiff Oncology-$41.44M-$0.93N/AN/AN/A-8,492.01%-50.13%-44.31%5/2/2024 (Estimated)Latest ADVM, CGTX, CRDF, and AXLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023CGTXCognition Therapeutics-$0.38-$0.27+$0.11-$0.27N/AN/A3/18/2024Q4 2023ADVMAdverum Biotechnologies-$2.80-$2.30+$0.50-$2.30N/AN/A2/29/2024Q4 2023CRDFCardiff Oncology-$0.26-$0.21+$0.05-$0.21$0.08 million$0.16 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AAXLAAxcella HealthN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A4.134.13AXLAAxcella HealthN/A0.800.80CGTXCognition TherapeuticsN/A3.373.37CRDFCardiff OncologyN/A7.417.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%AXLAAxcella Health65.07%CGTXCognition Therapeutics43.35%CRDFCardiff Oncology16.29%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies5.30%AXLAAxcella Health2.20%CGTXCognition Therapeutics23.80%CRDFCardiff Oncology6.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies12120.76 million19.66 millionOptionableAXLAAxcella Health112.95 million2.88 millionOptionableCGTXCognition Therapeutics2539.00 million29.72 millionNot OptionableCRDFCardiff Oncology3144.68 million41.86 millionOptionableADVM, CGTX, CRDF, and AXLA HeadlinesSourceHeadlineCardiff Oncology, Inc. (NASDAQ:CRDF) Forecasted to Earn Q1 2025 Earnings of ($0.28) Per Sharemarketbeat.com - April 12 at 6:40 AMElection Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?investorplace.com - April 9 at 4:30 PMCardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Studyglobenewswire.com - April 8 at 4:05 PMCardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Whyzacks.com - April 1 at 9:51 AMCardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Updatemarketbeat.com - March 28 at 3:45 PMbluebird bio falls as accounting errors force restatementsmsn.com - March 27 at 9:25 AMFinding the Next Big Winners: 3 Stocks You Can Snag for Under $5investorplace.com - March 21 at 4:05 PMCardiff (CRDF) Stock Rallies 194% in a Month: Here's Whyzacks.com - March 21 at 8:56 AMREGN Mar 2024 982.500 callfinance.yahoo.com - March 16 at 9:32 AMREGN Mar 2024 1010.000 putfinance.yahoo.com - March 16 at 9:32 AMCRDF Apr 2024 2.500 callfinance.yahoo.com - March 15 at 2:47 PMCRDF Nov 2024 10.000 putfinance.yahoo.com - March 15 at 8:29 AMCRDF Apr 2024 5.000 callfinance.yahoo.com - March 15 at 1:03 AMREGN Mar 2024 992.500 callfinance.yahoo.com - March 14 at 8:03 PMHere's Why Momentum in Cardiff Oncology (CRDF) Should Keep goingzacks.com - March 14 at 9:51 AMCardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?zacks.com - March 14 at 9:11 AMCardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)seekingalpha.com - March 8 at 8:26 PMCardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024globenewswire.com - March 6 at 4:05 PMWhat Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?zacks.com - March 6 at 1:01 PMCardiff Oncology Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 3 at 9:19 AMCardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 2 at 9:02 AMCardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 2 at 9:02 AMNasdaq Surges 100 Points; ISM Manufacturing PMI Falls In Februarymsn.com - March 1 at 3:02 PMSmall Cap-Cardiff Oncology Outlines Data From Discontinued Colorectal Cancer Trial, Stock Soarsmsn.com - March 1 at 3:02 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdverum BiotechnologiesNASDAQ:ADVMAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Axcella HealthNASDAQ:AXLAAxcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Cognition TherapeuticsNASDAQ:CGTXCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.Cardiff OncologyNASDAQ:CRDFCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.